New research published in the Annals of Internal Medicine suggests the price tag on Sanofi and Regeneron’s cholesterol-lowering drug, Praluent, is not cost-effective despite a recent price decrease, pharmaphorum reports.
The study, which was based on results from the ODYSSEY OUTCOMES trial, suggests the drug’s price would need to be priced at $874-$2,311 to be cost effective.
Pointing to cheaper and effective generics, the study says Praluent’s pricing is tough to justify.
“Your additional drugs have to work harder to be cost-effective,” the study’s author, Dr. Dhruv Kazi, said.
To read the full report on pharmaphorum, click here.
